Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
University of Guelph
$211,250.00
Identification and validation of nutraceuticals that prevent SARS-CoV-2 infection
EF 2020-21
Résumé
COVID-19 is a significant global health burden and new strategies are needed to reduce the risk of SARS-CoV-2 infection.
In this project, we will test nutraceuticals (i.e., bioactive molecules from food) to see if they bind to and inhibit the entry of the virus into the cell. Interestingly, using computer modeling, nutraceuticals have been predicted to bind to SARS-CoV-2. In aim 1, we will directly test if nutraceuticals bind to the virus and prevent its entry into the cell. In aim 2, we will determine the dosing strategy (i.e., how much and how often you need to take the supplement so that the nutraceutical can get to the lungs and bind to the virus) to provide maximal protection. In aim 3, we will test the nutraceuticals anti-viral effects in mouse models.
Through this work, we will directly determine which nutraceutical can bind to and inhibit SARS-CoV-2 infection and provide a new approach to reducing the risk of infection.
Programme
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429576
Name
Spagnuolo Paul
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
COVID-19 Rapid Research - Therapeutics
Projecttitle
Identification and validation of nutraceuticals that prevent SARS-CoV-2 infection
Programtype2
Operating Grants
Orgnameinp2
University of Guelph
Cihramount2
$211,250
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Keyworddelim
Covid-19; Hace2; Nutraceuticals; Pharmacokinetics; Prevent Infection; S-Glycoprotein; Sars-Cov-2
Abstract
COVID-19 is a significant global health burden and new strategies are needed to reduce the risk of SARS-CoV-2 infection.
In this project, we will test nutraceuticals (i.e., bioactive molecules from food) to see if they bind to and inhibit the entry of the virus into the cell. Interestingly, using computer modeling, nutraceuticals have been predicted to bind to SARS-CoV-2. In aim 1, we will directly test if nutraceuticals bind to the virus and prevent its entry into the cell. In aim 2, we will determine the dosing strategy (i.e., how much and how often you need to take the supplement so that the nutraceutical can get to the lungs and bind to the virus) to provide maximal protection. In aim 3, we will test the nutraceuticals anti-viral effects in mouse models.
Through this work, we will directly determine which nutraceutical can bind to and inhibit SARS-CoV-2 infection and provide a new approach to reducing the risk of infection.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Spagnuolo, Paul
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $211,250~ $0~